COMMENTARY

Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls

December 28, 2017
By Yoshinori Sagehashi Japan’s all-important reimbursement policy panel adopted the government’s drug pricing reform package, with a significant reduction in the scope of eligible on-patent products for the so-called price maintenance premium (PMP). On an off-patent drug front, long-listed products…

To read the full story

COMMENTARY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…